F 4614
Latest Information Update: 28 Aug 2002
At a glance
- Originator Ishihara Sangyo Kaisha
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Mar 1999 New profile
- 04 Mar 1999 Preclinical development for Cancer in Japan (Unknown route)